Key Takeaways Kymera received FDA Fast Track for KT-621 to treat moderate to severe atopic dermatitis.KT-621 showed positive phase Ib results across biomarkers, clinical activity, comorbidities and safety.A phase IIb AD study is underway with mid-2027 data expected, and an asthma phase IIb study begins in 2026.Kymera Therapeutics, Inc. (KYMR) recently announced that the FDA granted Fast Track designation to pipeline candidate KT-621 for the treatment of moderate to severe atopic dermatitis (AD), the most co ...